Zhitong Finance APP learned that CICC released a research report saying that it maintainsMinimally invasive medical care(00853) "Outperform the industry" rating, lowered the net loss forecast attributable to the parent company in 2022/23 by US $24/55 million to US $31/290 million, and dropped the target price by 5% to HK $23.4, which is 42.9% upside from the current stock price. The company's 1H22 revenue was US $405 million, a year-on-year increase of 5.3%, and a year-on-year increase of 10.1% after excluding the impact of exchange rates. The loss attributable to equity shareholders expanded to US $198 million year-on-year, lower than the bank and market expectations.According to the report, the Shanghai Medical Insurance Bureau included TAVR consumables in the scope of medical insurance in May (75-80% reimbursement); In July, Beijing Medical Insurance Bureau announced the DRG exclusion payment method for innovative devices; In response to the proposal of the National People's Congress in August, National Healthcare Security Administration stated that it was studying and improving relevant policies to guide all localities to promptly implement qualifiedInnovative medical careDevices are included in the scope of medical insurance payment. Since 2022, the results of centralized procurement of pacemakers, coronary drug balls and intracranial coils have tended to be mild, and the electrophysiology of the spine and heart has also formulated reasonable grouping bidding rules based on specific conditions.The bank believes that the policy side's support for products with true technological innovation and clinical benefits is becoming increasingly clear, and expects various favorable policies to accelerate the use of TAVR and surgeryRobotThe volume of domestic innovative devices represented by Minimally Invasive is good for platform-based domestic innovative medical device companies represented by Minimally Invasive.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments